Arcadia, California 91006

  • Macular Degeneration

Purpose:

The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).


Criteria:

Inclusion Criteria: - Male or female participants, 50 years of age or older at the time of informed consent - Best Corrected Visual Acuity (BCVA) ≤ 78 and ≥ 24 letters (20/32 to 20/320 Snellen equivalents, respectively) at Screening and at Baseline (Day 1, prior to treatment) visits in the study eye - BCVA of 34 letters (Snellen equivalent 20/200) or better at Baseline (Day 1, prior to treatment) in the non-study eye Exclusion Criteria: - Active periocular, ocular, or intraocular infection at baseline (Day 1) (either eye) - Previous or concurrent macular laser treatment (study eye) - Cataract or refractive surgery within 3 months prior to baseline (study eye)


NCT ID:

NCT03539549


Primary Contact:

Study Director
Joanne Li, MD
Allergan


Backup Contact:

N/A


Location Contact:

Arcadia, California 91006
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 02, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.